Graft-versus-host disease (GVHD) is a life-threatening condition that can occur after an allogeneic stem cell transplant, which is a procedure that some blood cancer patients choose as it may offer ...

MaaT Pharma to Present Four Abstracts at the 52nd EBMT Annual Meeting and to Highlight Clinigen-Hosted Industry Symposium on acute GvHD Management ...

Posttransplant cyclophosphamide–containing prophylaxis correlated with lower aGVHD risk than tacrolimus/methotrexate, and ATG/alemtuzumab use contributed to risk estimation. Clinical utility includes ...

Learn coping strategies and tips to manage sexual problems from chronic GVHD.

There are now more drugs than ever to treat and prevent graft-versus-host disease in patients with blood cancer who receive a stem cell transplant. For many patients with blood cancers, an allogeneic ...

Risk of graft-vs.-host disease, an often-debilitating and sometimes-deadly bone marrow transplant complication, can be reduced by matching key immune genes in a transplant recipient and their donor.

Patients undergoing matched-donor stem cell transplants lived four times longer without episodes of graft-versus-host disease (GVHD) with post-transplant cyclophosphamide-cyclosporin prophylaxis, a ...